<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is a cluster of metabolic and inflammatory abnormalities including <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The fatty acid binding proteins aP2 (fatty acid binding protein [FABP]-4) and mal1 (FABP5) are closely related and both are expressed in adipocytes </plain></SENT>
<SENT sid="2" pm="."><plain>Previous studies in aP2-deficient mice have indicated a significant role for aP2 in <z:hpo ids='HP_0001513'>obesity</z:hpo>-related <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>However, the biological functions of mal1 are not known </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we report the generation of mice with targeted null mutations in the mal1 gene as well as transgenic mice overexpressing mal1 from the aP2 promoter/enhancer to address the role of this FABP in metabolic regulation in the presence or absence of <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>To address the role of the second adipocyte FABP in metabolic regulation in the presence and deficiency of <z:hpo ids='HP_0001513'>obesity</z:hpo>, absence of mal1 resulted in increased systemic insulin sensitivity in two models of <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Adipocytes isolated from mal1-deficient mice also exhibited enhanced insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> transport capacity </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, mice expressing high levels of mal1 in adipose tissue display reduced systemic insulin sensitivity </plain></SENT>
<SENT sid="8" pm="."><plain>Hence, our results demonstrate that mal1 modulates adipose tissue function and contributes to systemic <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism and constitutes a potential therapeutic target in <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
</text></document>